Clinical trials: Antiviral Agents
Periodontitis Chronic Generalized Severe
Contribution of an Antiviral Drug (Valaciclovir) in the Treatment of Generalized Periodontitis (Stage III or IV and Grade A, B or C): Prospective, Randomized and Double Blind Clinical Trial
Periodontitis is an inflammatory pathology that destroys periodontitis and causes tooth loosening. Its high incidence, combined with very high oral and systemic morbidity, places this pathology at the heart of global public…
- Trial name
- HERPARO (NCT05902208)
- Testing
- Antiviral treatment with conventional non-surgical treatment
- Where
- 3 sites in France
- Volunteers
- 142 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
HIV Infections
A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs
To evaluate the antiviral activity and safety of two formulations of saquinavir in combination with licensed nucleoside antiretroviral drugs.
- Trial name
- NCT00002162
- Testing
- Saquinavir, Lamivudine, Stavudine
- Where
- 27 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease
Non-Invasive Risk Stratification for Hepatocellular Carcinoma in HCV-Related Compensated Advanced Chronic Liver Disease Following Sustained Virological Response: Validation of the aMAP Score
This retrospective cohort study evaluated the performance of non-invasive risk scores for predicting de novo hepatocellular carcinoma in adults with hepatitis C virus-related compensated advanced chronic liver disease who…
- Conditions
- Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease, Hepatocellular Carcinoma (HCC)
- Trial name
- HCV-aMAP (NCT07687758)
- Testing
- Non-invasive Risk Score Assessment
- Where
- Thailand
- Volunteers
- 571 people
- Sponsor
- Siriraj Hospital
Hepatocellular Carcinoma, Hepatitis C
Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence
Background and Aims: Arrival of direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) with high-sustained virological response (SVR) rates and very few side effects has drastically changed the management of HCV…
- Conditions
- Hepatocellular Carcinoma, Hepatitis C, Direct Acting Antivirals
- Trial name
- RECAR (NCT03197155)
- Testing
- Direct Acting Antivirals against hepatitis C virus infection
- Volunteers
- 68 people
- Sponsor
- Hospices Civils de Lyon
Hepatitis B, Chronic
A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus Infection
This is a double-blinded, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics, and antiviral activity in both healthy volunteers and volunteers with chronic hepatitis B virus infection.
- Trial name
- NCT04248426
- Testing
- ATI-2173
- Where
- 3 sites in Canada, Moldova and 1 more
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Antios Therapeutics, Inc
Cytomegalovirus Retinitis, HIV Infections
Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection
The purpose of this study is to make valganciclovir available, before it is approved for marketing, to HIV-infected patients who have cytomegalovirus (CMV) retinitis (eye infection) and cannot take drugs by injection.
- Trial name
- NCT00017784
- Testing
- Valganciclovir
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B Virus (HBV)
Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) in Chronic Hepatitis B Patients
Hepatitis B virus (HBV) infection is a worldwide health problem. It has been proved that the persistence of HBV is associated with the failure to stimulate an efficient HBV-specific immune response.
- Trial name
- NCT04168333
- Testing
- T101 Group
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tasly Tianjin Biopharmaceutical Co., Ltd.
HIV Infection
Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor
This study will continue to follow children who participated in an earlier National Cancer Institute trial of HIV treatment with a protease inhibitor.
- Trial name
- NCT00001826
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Hepatitis C, Hepatocellular Carcinoma
Direct Acting Antiviral-Post Authorization Safety Study
This is an independent optional sub-study parallel to TARGET-HCC (NCT02954094). The purpose of Direct-Acting Antiviral-Post Authorization Safety Study (DAA-PASS) is to investigate the impact of exposure to direct-acting…
- Trial name
- NCT03707080
- Where
- 62 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- Target PharmaSolutions, Inc.
Chronic Hepatitis c
Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy
Hepatitis C virus (HCV) is one of the major globally cause of death and morbidity.Chronic hepatitis C is the leading cause of end-stage liver disease, hepatocellular carcinoma and liver-related death in Egypt.It could be…
- Trial name
- NCT03612973
- Testing
- lipid profile, fasting insulin, fibro scan
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Assiut University
HIV Infections
A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes
To determine the maximum tolerated dose (MTD) of hypericin, to define the types of toxicities that may be observed, and to determine what doses of the drug are associated with improvements in virological and immunological…
- Trial name
- NCT00000645
- Testing
- Hypericin
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
PrEP, PrEP Adherence Experiences
PrEP-LANA (Pre-exposure Prophylaxis- Long-acting Novel Antiviral Agent)
The goal of this 12-month implementation science study is to generate the evidence required to ensure long-acting cabotegravir (LA CAB) as pre-exposure prophylaxis (PrEP) can be delivered in an equitable manner within the NHS.
- Conditions
- PrEP, PrEP Adherence Experiences, PrEP Adherence Perspectives, PrEP Uptake
- Trial name
- PrEP-LANA (NCT07620730)
- Volunteers
- 220 people
- Sponsor
- Queen Mary University of London
Liver Cirrhosis, Chronic Hepatitis B
Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB)
Antiviral treatment on Chronic Hepatitis B (CHB) patients with liver cirrhosis is compulsory and effective. Telbivudine, which is superior to lamivudine in the treatment of CHB,is considered to be appropriate for the antiviral…
- Trial name
- NCT01380951
- Testing
- telbivudine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The Fifth People's Hospital of Suzhou
Covid19
Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19
The 2020 pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emergency. COVID-19 appears to be a disease with an early phase where the virus replicates, coinciding with first presentation of symptoms…
- Trial name
- FANTAZE (NCT04918927)
- Testing
- Favipiravir, Nitazoxanide
- Where
- Mexico
- Volunteers
- 120 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Influenza
Evaluation of Alternative Oseltamivir (Tamiflu) Dosing Strategies.
Objective 1: Determine the safety and toxicity profile of Tamiflu administered in combination with probenecid in healthy adults.Objective 2: Determine the pharmacokinetic profile of Tamiflu and probenecid in healthy adults.
- Trial name
- NCT00304434
- Testing
- Oseltamivir, Probenecid
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Liver Cirrhosis, Experimental
Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis
To evaluate: 1. the impact of combined antiviral therapy (Peginterferon plus ribavirin) on natural history of patients affected with HCV decompensated cirrhosis, after sustained virological response. A controlled study. 2.
- Trial name
- NCT00301509
- Testing
- peginterferon and ribavirin
- Where
- Italy
- Volunteers
- healthy volunteers welcome
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Hepatitis B Infection, Malignant Solid Neoplasm
Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors
This phase III trial studies the effect of hepatitis B antiviral (anti-HBV) therapy in preventing liver complications in patients with chronic or past hepatitis B virus (HBV) who are receiving anti-cancer therapy for solid…
- Trial name
- NCT03887702
- Testing
- Best Practice, Entecavir, Tenofovir Alafenamide
- Where
- 193 sites in United States, Guam
- Volunteers
- 4 people
- Sponsor
- SWOG Cancer Research Network
Hepatitis C, Chronic
Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera
Hepatitis C virus (HCV) infection is associated with significant morbidity and mortality owing to progression of a high percentage (85%) of HCV infected patients to chronic hepatitis, which might lead to the development of liver…
- Trial name
- NCT03882307
- Testing
- sofosbuvir and daclatasvir
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
Hepatitis B
Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy
The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Positive lymphoma patients treated with rituximab-based immunochemotherapy.
- Trial name
- NCT01768195
- Testing
- Entecavir prophylaxis
- Where
- 13 sites in China
- Volunteers
- 80 people
- Sponsor
- Peking University
Hepatitis C, Oxidative Stress
Blood Antioxidant Status in Chronic Hepatitis C Patients Before and After Antioxidant Supplementation: a Randomized Clinical Trial
The objective of the present study is to evaluate the antioxidant status in the blood of HCV patients treated with pegylated interferon (2a 1.5 ug/kg; 2b 180 ug) combined with ribavirin (1000 to 1250 mg) before and after…
- Trial name
- HepCAntSup (NCT00983164)
- Testing
- Antioxidant Supplementation
- Where
- 3 sites in Brazil
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Universidade do Sul de Santa Catarina
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.